Login / Signup

Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.

Meg J JardineZien ZhouKenneth W MahaffeyMegumi OshimaRajiv AgarwalGeorge L BakrisHarpreet S BajajScott BullChristopher P CannonDavid M CharytanDick de ZeeuwGian Luca Di TannaTom GreeneHiddo J L HeerspinkAdeera LevinBruce NealCarol PollockRose QiuTao SunDavid C WheelerHong ZhangBernard ZinmanNorman RosenthalVlado Perkovicnull null
Published in: Journal of the American Society of Nephrology : JASN (2020)
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE), NCT02065791.
Keyphrases
  • diabetic nephropathy
  • metabolic syndrome
  • adipose tissue
  • skeletal muscle
  • insulin resistance
  • weight loss